A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Sponsor: Regeneron Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS1963
U.S. Govt. ID: NCT03005782
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to find a safe dose level of REGN3767 alone or in combination with REGN2810. Other purposes of this study are to measure the levels of REGN3767 alone or in combination with REGN2810 in your blood and to collect any evidence of tumor shrinkage when given alone or in combination with REGN2810. These drugs are not yet approved.
This study is closed
Investigator
Alexander Wei, MD
Do You Qualify?
Do you have breast, lung, melanoma, or thyroid cancer? Yes No
Does your cancer continue to grow even after receiving treatment, or is there no available therapy for your cancer? Yes No
Are you 18 years of age or older? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE